One and 2-year survival by age group and trial status
Trial status | Age group | Number of patients | Deaths | Survival (%) | 95% CI | p Value |
One-year survival | ||||||
Trial | 15–19 | 203 | 17 | 91.7 | 86.9 to 94.7 | <0.001 |
Non-trial | 134 | 30 | 77.6 | 69.6 to 83.8 | ||
Trial | 20–24 | 36 | 5 | 86.2 | 69.8 to 94.0 | 0.969 |
Non-trial | 130 | 18 | 86.2 | 79.0 to 91.1 | ||
Trial | 15–24 | 239 | 22 | 90.8 | 86.4 to 93.9 | 0.004 |
Non-trial | 264 | 48 | 81.9 | 76.6 to 86.0 | ||
2 year conditional on 1-year survival | ||||||
Trial | 15–19 | 186 | 10 | 94.7 | 90.3 to 97.1 | 0.008 |
Non-trial | 104 | 16 | 84.7 | 76.2 to 90.4 | ||
Trial | 20–24 | 31 | 3 | 90.4 | 73.0 to 96.9 | 0.236 |
Non-trial | 112 | 22 | 80.4 | 71.8 to 86.7 | ||
Trial | 15–24 | 217 | 13 | 94.1 | 90.0 to 96.6 | 0.001 |
Non-trial | 216 | 38 | 82.5 | 76.7 to 87.0 | ||
Two-year survival | ||||||
Trial | 15–19 | 203 | 27 | 86.8 | 81.3 to 90.7 | <0.001 |
Non-trial | 134 | 46 | 65.7 | 57.0 to 73.1 | ||
Trial | 20–24 | 36 | 8 | 77.9 | 60.5 to 88.3 | 0.381 |
Non-trial | 130 | 40 | 69.3 | 60.6 to 76.5 | ||
Trial | 15–24 | 239 | 35 | 85.4 | 80.3 to 89.3 | <0.001 |
Non-trial | 264 | 86 | 67.5 | 61.5 to 72.8 |